Phathom Pharmaceuticals Stock Alpha and Beta Analysis
| PHAT Stock | USD 15.71 0.88 5.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Phathom Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Phathom Pharmaceuticals over a specified time horizon. Remember, high Phathom Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Phathom Pharmaceuticals' market risk premium analysis include:
Beta 1.23 | Alpha 0.41 | Risk 3.14 | Sharpe Ratio 0.17 | Expected Return 0.54 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Phathom Pharmaceuticals Backtesting, Phathom Pharmaceuticals Valuation, Phathom Pharmaceuticals Correlation, Phathom Pharmaceuticals Hype Analysis, Phathom Pharmaceuticals Volatility, Phathom Pharmaceuticals History and analyze Phathom Pharmaceuticals Performance. Phathom Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Phathom Pharmaceuticals market risk premium is the additional return an investor will receive from holding Phathom Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Phathom Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Phathom Pharmaceuticals' performance over market.| α | 0.41 | β | 1.23 |
Phathom Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Phathom Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Phathom Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Phathom Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Phathom Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Phathom Pharmaceuticals shares will generate the highest return on investment. By understating and applying Phathom Pharmaceuticals stock market price indicators, traders can identify Phathom Pharmaceuticals position entry and exit signals to maximize returns.
Phathom Pharmaceuticals Return and Market Media
The median price of Phathom Pharmaceuticals for the period between Sun, Oct 5, 2025 and Sat, Jan 3, 2026 is 14.41 with a coefficient of variation of 11.42. The daily time series for the period is distributed with a sample standard deviation of 1.63, arithmetic mean of 14.26, and mean deviation of 1.25. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Phathom projects 1B GI market opportunity as sales realignment drives 25 percent revenue growth | 10/30/2025 |
2 | Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals Long-Term Strategy - Yahoo Finance | 11/12/2025 |
3 | Is Phathom Pharmaceuticals Inc. stock a contrarian buy - Weekly Trading Summary Risk Managed Investment Strategies - newser.com | 11/18/2025 |
4 | Phathom Pharmaceuticals Superior Efficacy Drives Vonoprazan Growth - Seeking Alpha | 11/21/2025 |
5 | Phathom Pharmaceuticals Upgraded at Barclays | 12/11/2025 |
6 | Disposition of 31502 shares by Basta Steven L of Phathom Pharmaceuticals at 15.36 subject to Rule 16b-3 | 12/17/2025 |
7 | Phathom Pharmaceuticals Reaches New 1-Year High Whats Next | 12/18/2025 |
8 | Disposition of 8750 shares by Parikh Asit of Phathom Pharmaceuticals at 10.3 subject to Rule 16b-3 | 12/19/2025 |
9 | Acquisition by Parikh Asit of 8750 shares of Phathom Pharmaceuticals at 10.3 subject to Rule 16b-3 | 12/23/2025 |
10 | Acquisition by Sanjeev Narula of 42848 shares of Phathom Pharmaceuticals at 15.71 subject to Rule 16b-3 | 01/02/2026 |
About Phathom Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Phathom or other stocks. Alpha measures the amount that position in Phathom Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 | 2026 (projected) | Interest Debt Per Share | 9.92 | 8.93 | 9.38 | Revenue Per Share | 0.87 | 0.79 | 0.83 |
Phathom Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Phathom Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Phathom Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Phathom Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Phathom Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Phathom Pharmaceuticals' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Phathom Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.